Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar 1;179(3):316-323.
doi: 10.1001/jamainternmed.2018.6226.

Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia

Pranita D Tamma  1 , Anna T Conley  2 , Sara E Cosgrove  3 , Anthony D Harris  4 , Ebbing Lautenbach  5 , Joe Amoah  1 , Edina Avdic  6 , Pam Tolomeo  5 , Jacqueleen Wise  5 , Sonia Subudhi  7 , Jennifer H Han  5 ; Antibacterial Resistance Leadership Group
Affiliations
Multicenter Study

Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia

Pranita D Tamma et al. JAMA Intern Med. .

Erratum in

  • Error in Figure 3.
    [No authors listed] [No authors listed] JAMA Intern Med. 2019 Nov 1;179(11):1607. doi: 10.1001/jamainternmed.2019.5480. JAMA Intern Med. 2019. PMID: 31682686 Free PMC article. No abstract available.

Abstract

Importance: Conversion to oral therapy for Enterobacteriaceae bacteremia has the potential to improve the quality of life of patients by improving mobility, eliminating catheter-associated discomfort, decreasing the risk for noninfectious and infectious catheter-associated adverse events, and decreasing health care costs.

Objective: To compare the association of 30-day mortality with early oral step-down therapy vs continued parenteral therapy for the treatment of Enterobacteriaceae bloodstream infections.

Design, setting, and participants: This retrospective multicenter cohort study included a 1:1 propensity score-matched cohort of 4967 unique patients hospitalized with monomicrobial Enterobacteriaceae bloodstream infection at 3 academic medical centers from January 1, 2008, through December 31, 2014. Eligibility criteria included appropriate source control measures, appropriate clinical response by day 5, active antibiotic therapy from day 1 until discontinuation of therapy, availability of an active oral antibiotic option, and ability to consume other oral medications or feeding. Statistical analysis was performed from March 2, 2018, to June 2, 2018.

Exposures: Oral step-down therapy within the first 5 days of treatment of Enterobacteriaceae bacteremia.

Main outcomes and measures: The main outcome was 30-day all-cause mortality.

Results: Of the 2161 eligible patients, 1185 (54.8%) were male and 1075 (49.7%) were white; the median (interquartile range [IQR]) age was 59 (48-68) years. One-to-one propensity-score matching yielded 1478 patients, with 739 in each study arm. Sources of bacteremia included urine (594 patients [40.2%]), gastrointestinal tract (297 [20.1%]), central line-associated (272 [18.4%]), pulmonary (58 [3.9%]), and skin and soft tissue (41 [2.8%]). There were 97 (13.1%) deaths in the oral step-down group and 99 (13.4%) in the intravenous (IV) group within 30 days (hazard ratio [HR], 1.03; 95% CI, 0.82-1.30). There were no differences in recurrence of bacteremia within 30 days between the groups (IV, 6 [0.8%]; oral, 4 [0.5%]; HR, 0.82 [0.33-2.01]). Patients transitioned to oral step-down therapy were discharged from the hospital an average of 2 days (IQR, 1-6) sooner than patients who continued to receive IV therapy (5 days [IQR, 3-8 days] vs 7 days [IQR, 4-14 days]; P < .001).

Conclusions and relevance: In this study, 30-day mortality was not different among hospitalized patients who received oral step-down vs continued parenteral therapy for the treatment of Enterobacteriaceae bloodstream infections. The findings suggest that transitioning to oral step-down therapy may be an effective treatment approach for patients with Enterobacteriaceae bacteremia who have received source control and demonstrated an appropriate clinical response. Early transition to oral step-down therapy may be associated with a decrease in the duration of hospital stay for patients with Enterobacteriaceae bloodstream infections.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tamma reported receiving an investigator-initiated research grant from Merck unrelated to this work. Dr Cosgrove reported receiving consulting fees from Novartis and Theravance unrelated to this manuscript. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. General Eligibility Criteria for the Study Sample
All patients received at least 7 days of treatment, with a range of 7 to 15 days. IV indicated intravenous.
Figure 2.
Figure 2.. Standardized Mean Biases Comparing the Full Unmatched Cohort With the Propensity Score–Matched Cohort
ICU indicates intensive care unit.
Figure 3.
Figure 3.. Probability of 30-Day Survival in the Propensity Score–Matched Cohort
See this image and copyright information in PMC

Comment in

References

    1. Suljagić V, Cobeljić M, Janković S, et al. . Nosocomial bloodstream infections in ICU and non-ICU patients. Am J Infect Control. 2005;33(6):333-340. doi:10.1016/j.ajic.2005.03.010 - DOI - PubMed
    1. Mermel LA, Allon M, Bouza E, et al. . Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2010;50(7):1079]. Clin Infect Dis. 2009;49(1):1-45. doi:10.1086/599376 - DOI - PMC - PubMed
    1. Rieger KL, Bosso JA, MacVane SH, Temple Z, Wahlquist A, Bohm N. Intravenous-only or intravenous transitioned to oral antimicrobials for Enterobacteriaceae-associated bacteremic urinary tract infection. Pharmacotherapy. 2017;37(11):1479-1483. doi:10.1002/phar.2024 - DOI - PMC - PubMed
    1. Talan DA, Stamm WE, Hooton TM, et al. . Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583-1590. doi:10.1001/jama.283.12.1583 - DOI - PubMed
    1. Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol. 2004;171(2 Pt 1):734-739. doi:10.1097/01.ju.0000106191.11936.64 - DOI - PubMed

Publication types

Substances